Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose ampicillin-sulbactam plus tigecycline vs colistin for VAP due to XDR Acinetobacter baumannii
IRCT20251220068393N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in ventilator-associated pneumonia (VAP) and Acinetobacter baumannii pneumonia comparing High-dose ampicillin-sulbactam + tigecycline with High-dose ampicillin-sulbactam + colistin (2 arms). Started Jan 2026; status: completed.
02
Drugs
ampicillin + sulbactamtigecyclinecolistin
03
Conditions
ventilator-associated pneumonia (VAP)Acinetobacter baumannii pneumonia
Beyond the preview
Go deeper on IRCT20251220068393N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251220068393N1.